dysesthesia tirzepatide What is the appropriate evaluation and management of new peripheral paresthesia and pruritus after starting (Mounjaro) for diabetes? How Tirzepatide Affects Your Body

Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke

Weight regain after discontinuation is commonsemaglutide is typically considered a long-term maintenance therapy, not a time-limited intervention

What the Numbers Show Average weight loss by timepoint: Week 12: 8.7% total body weight (19 pounds for 220-pound person) Week 24: 17.3% total body weight (38 pounds for 220-pound person) Week 36: 21.1% total body weight (46 pounds for 220-pound person) Week 48: 24.2% total body weight (53 pounds for 220-pound person) Data from Phase 2 clinical trial, 12mg dose cohort

Payers are signaling willingness to reimburse premium-priced multi-agonists if cardiovascular or renal benefits materialize, a possibility under investigation in ongoing SURMOUNT-5 and TRIUMPH-2 outcome studies